Burrell International Group (on Behalf of Amo Pharma)
Life Sciences R&D
AI Overview
With $0 in lobbying spend across 3 quarterly filings, Burrell International Group (on Behalf of Amo Pharma) is an active lobbying client. Their lobbying covers 1 issue area.
Spending Trend
View as table
| Year | Lobbying Spend |
|---|---|
| 2025 | $0 |
Issues Lobbied
Lobbying Firms
Lobbyists
Government Agencies Targeted
These are the government entities that Burrell International Group (on Behalf of Amo Pharma) disclosed contacting in their lobbying filings.
What They Lobby About
These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Health Issues
Rare disease issues; FDA policies
Clinical trial guidance for ultra-rare and rare diseases.
Related Analysis
Related Investigations
Similar Clients
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.